肿瘤坏死因子相关配体与阿司匹林合用对肝癌SMMC-7721细胞凋亡的影响  

Cooperative anti-tumor effect of aspirin and TNF-related apoptosis-inducing ligand

作　　者：李小安[1] 房殿春[1] 司佩任[1] 张汝刚[1] 杨柳芹[1] 

机构地区：[1]第三军医大学西南医院全军消化专科中心,重庆400038

出　　处：《中华肝脏病杂志》2003年第11期676-679,共4页Chinese Journal of Hepatology

基　　金：全军"十五"科研基金资助项目(01MA172)

摘　　要：目的 观察肿瘤坏死因子相关的凋亡诱导配体(TRAIL)与阿司匹林合用对肝癌SMMC-7721细胞的作用。 方法 氨甲喋呤法检测SMMC-7721细胞存活分数;流式细胞仪检测SMMC-7721细胞的凋亡率和细胞周期;Western Blot法检测凋亡相关基因的表达。 结果 单用300 ng/ml TRAIL、3、10 mmol/L阿司匹林SMMC-7721细胞存活分数分别为82.76％、81.34％和71.29％,合用的存活分数分别为43.5％、37.8％。3、10 mmol/L阿司匹林与300 ng/ml TRAIL合用诱导的细胞凋亡率明显大于单用两药诱导的细胞凋亡率之和(单用300 ng/ml TRAIL、3 mmol/L和10 mmol/L阿司匹林凋亡率分别为21.25％、1.89％和6.08％,合用的凋亡率分别34.76％、38.56％)并使G0/G1期细胞增加;3、10 mmol/L的阿司匹林使SMMC-7721细胞Bcl-2的表达明显减弱,但对Bax的表达无影响。 结论TRAIL与阿司匹林合用对肝癌SMMC-7721细胞有明显的协同杀伤作用,其机制可能与阿司匹林抑制Bcl-2的表达有关。Objective To observe the anti-tumor effect of combination TNF-related apoptosis-inducing ligand (TRAIL) with aspirin on liver cancer cell line, SMMC-7721. Methods The survival fraction of SMMC-7721 cells was measured by MTT assay, apoptosis rate and cell cycle was determined by flow cytometry, and the expression of apoptosis-related gene was identified by western blot. Results The survival fraction of SMMC-7721 cells treated with 300 ng/ml TRAIL, 3 mmol/L or 10 mmol/L aspirin alone was 82.76%, 81.34% and 71.29% respectively, and the survival fractions of SMMC-7721 cells treated with TRAIL and 3 mmol/L or 10 mmol/L aspirin were 43.54% and 37.8% respectively. The apoptosis rates of SMMC-7721 cells induced by TRAIL and 3 mmol/L or10 mmol/L aspirin were higher than that induced by TRAIL or aspirin alone (34.76% and 38.56% vs 21.25%, 1.89% and 6.08%), and G0/G1 arrest was observed under TRAIL and aspirin. The expression of Bcl-2 in SMMC-7721 cells treated by 3 mmol/L or 10 mmol/L aspirin decreased markedly, but no effect on Bax. Conclusion The cooperative anti-tumor effect of aspirin and TRAIL may be related to the inhibition of the expression of Bcl-2 by aspirin.

关 键 词：肿瘤坏死因子 阿司匹林 肝癌 SMMC-772l细胞 细胞凋亡 凋亡诱导配体 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]